Cargando…
Targeted repositioning identifies drugs that increase fibroblast growth factor 20 production and protect against 6-hydroxydopamine-induced nigral cell loss in rats
Endogenous fibroblast growth factor 20 (FGF20) supports maintenance of dopaminergic neurones within the nigrostriatal pathway. Moreover, direct intracerebral infusion of FGF20 protects against nigrostriatal tract loss in the 6-hydroxydopamine lesion rat model of Parkinson’s disease. Increasing endog...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6554393/ https://www.ncbi.nlm.nih.gov/pubmed/31171821 http://dx.doi.org/10.1038/s41598-019-44803-1 |
_version_ | 1783424960829587456 |
---|---|
author | Fletcher, Edward J. R. Jamieson, Aran D. Williams, Gareth Doherty, Patrick Duty, Susan |
author_facet | Fletcher, Edward J. R. Jamieson, Aran D. Williams, Gareth Doherty, Patrick Duty, Susan |
author_sort | Fletcher, Edward J. R. |
collection | PubMed |
description | Endogenous fibroblast growth factor 20 (FGF20) supports maintenance of dopaminergic neurones within the nigrostriatal pathway. Moreover, direct intracerebral infusion of FGF20 protects against nigrostriatal tract loss in the 6-hydroxydopamine lesion rat model of Parkinson’s disease. Increasing endogenous FGF20 production might provide a less-invasive, more translational way of providing such protection. Accordingly, we adopted a targeted repositioning approach to screen for candidate FDA-approved drugs with potential to enhance endogenous FGF20 production in brain. In silico interrogation of the Broad Institute’s Connectivity Map database (CMap), revealed 50 candidate drugs predicted to increase FGF20 transcription, 16 of which had profiles favourable for use in Parkinson’s disease. Of these, 11 drugs were found to significantly elevate FGF20 protein production in MCF-7 cells, between two- and four-fold. Four drugs were selected for examination in vivo. Following oral dosing in rats for 7 days, salbutamol and triflusal, but not dimethadione or trazodone, significantly elevated FGF20 levels in the nigrostriatal tract. Preliminary examination in the unilateral 6-hydroxydopamine-lesioned rat revealed a modest but significant protection against nigral cell loss with both drugs. Our data demonstrate the power of targeted repositioning as a method to identify existing drugs that may combat disease progression in Parkinson’s by boosting FGF20 levels. |
format | Online Article Text |
id | pubmed-6554393 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-65543932019-06-14 Targeted repositioning identifies drugs that increase fibroblast growth factor 20 production and protect against 6-hydroxydopamine-induced nigral cell loss in rats Fletcher, Edward J. R. Jamieson, Aran D. Williams, Gareth Doherty, Patrick Duty, Susan Sci Rep Article Endogenous fibroblast growth factor 20 (FGF20) supports maintenance of dopaminergic neurones within the nigrostriatal pathway. Moreover, direct intracerebral infusion of FGF20 protects against nigrostriatal tract loss in the 6-hydroxydopamine lesion rat model of Parkinson’s disease. Increasing endogenous FGF20 production might provide a less-invasive, more translational way of providing such protection. Accordingly, we adopted a targeted repositioning approach to screen for candidate FDA-approved drugs with potential to enhance endogenous FGF20 production in brain. In silico interrogation of the Broad Institute’s Connectivity Map database (CMap), revealed 50 candidate drugs predicted to increase FGF20 transcription, 16 of which had profiles favourable for use in Parkinson’s disease. Of these, 11 drugs were found to significantly elevate FGF20 protein production in MCF-7 cells, between two- and four-fold. Four drugs were selected for examination in vivo. Following oral dosing in rats for 7 days, salbutamol and triflusal, but not dimethadione or trazodone, significantly elevated FGF20 levels in the nigrostriatal tract. Preliminary examination in the unilateral 6-hydroxydopamine-lesioned rat revealed a modest but significant protection against nigral cell loss with both drugs. Our data demonstrate the power of targeted repositioning as a method to identify existing drugs that may combat disease progression in Parkinson’s by boosting FGF20 levels. Nature Publishing Group UK 2019-06-06 /pmc/articles/PMC6554393/ /pubmed/31171821 http://dx.doi.org/10.1038/s41598-019-44803-1 Text en © The Author(s) 2019 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Fletcher, Edward J. R. Jamieson, Aran D. Williams, Gareth Doherty, Patrick Duty, Susan Targeted repositioning identifies drugs that increase fibroblast growth factor 20 production and protect against 6-hydroxydopamine-induced nigral cell loss in rats |
title | Targeted repositioning identifies drugs that increase fibroblast growth factor 20 production and protect against 6-hydroxydopamine-induced nigral cell loss in rats |
title_full | Targeted repositioning identifies drugs that increase fibroblast growth factor 20 production and protect against 6-hydroxydopamine-induced nigral cell loss in rats |
title_fullStr | Targeted repositioning identifies drugs that increase fibroblast growth factor 20 production and protect against 6-hydroxydopamine-induced nigral cell loss in rats |
title_full_unstemmed | Targeted repositioning identifies drugs that increase fibroblast growth factor 20 production and protect against 6-hydroxydopamine-induced nigral cell loss in rats |
title_short | Targeted repositioning identifies drugs that increase fibroblast growth factor 20 production and protect against 6-hydroxydopamine-induced nigral cell loss in rats |
title_sort | targeted repositioning identifies drugs that increase fibroblast growth factor 20 production and protect against 6-hydroxydopamine-induced nigral cell loss in rats |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6554393/ https://www.ncbi.nlm.nih.gov/pubmed/31171821 http://dx.doi.org/10.1038/s41598-019-44803-1 |
work_keys_str_mv | AT fletcheredwardjr targetedrepositioningidentifiesdrugsthatincreasefibroblastgrowthfactor20productionandprotectagainst6hydroxydopamineinducednigralcelllossinrats AT jamiesonarand targetedrepositioningidentifiesdrugsthatincreasefibroblastgrowthfactor20productionandprotectagainst6hydroxydopamineinducednigralcelllossinrats AT williamsgareth targetedrepositioningidentifiesdrugsthatincreasefibroblastgrowthfactor20productionandprotectagainst6hydroxydopamineinducednigralcelllossinrats AT dohertypatrick targetedrepositioningidentifiesdrugsthatincreasefibroblastgrowthfactor20productionandprotectagainst6hydroxydopamineinducednigralcelllossinrats AT dutysusan targetedrepositioningidentifiesdrugsthatincreasefibroblastgrowthfactor20productionandprotectagainst6hydroxydopamineinducednigralcelllossinrats |